Utah Medical Products (DE:UTM)
FRANKFURT:UTM
UTM Stock Chart & Stats
€50.00
€0.50(0.87%)
At close: 4:00 PM EST
€50.00
€0.50(0.87%)
Day’s Range― - ―
52-Week Range€45.60 - €60.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€186.92M
Enterprise Value€124.38M
Total Cash (Recent Filing)€87.41M
Total Debt (Recent Filing)€210.00K
Price to Earnings (P/E)19.9
Beta0.30
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.30
Shares Outstanding3,184,025
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)1.55
Price to Sales (P/S)4.81
P/FCF Ratio12.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetNear-zero leverage and minimal debt versus a sizable equity base give the company durable financial flexibility. This conservatism lowers bankruptcy risk, supports capital allocation (buybacks, capex, M&A) and cushions shocks, strengthening resilience over the next 2–6 months and beyond.
High And Sustainable MarginsSustained gross and net margins well above peers indicate enduring pricing power and efficient operations. High margins support reinvestment, R&D and distributor relationships, enabling durable profitability even if top-line growth slows, preserving long-term cash generation capacity.
Strong Cash ConversionNearly one-to-one free cash flow to net income demonstrates high-quality earnings and dependable cash generation. This reliable conversion supports sustainable dividends, working capital needs and strategic initiatives, providing a durable foundation for shareholder returns and operational stability.
Bears Say
Persistent Revenue DeclineMulti-year top-line contraction erodes scale, limits operating leverage and constrains long-term growth options. Persistent revenue declines reduce ability to invest in new products or expand channels, increasing reliance on margin and cost control to sustain earnings over the medium term.
Softening Free Cash Flow TrendWhile cash conversion remains high, a roughly 9% TTM decline in free cash flow signals weakening operational cash generation. Continued FCF shrinkage would limit reinvestment, reduce the buffer for unexpected costs, and pressure capital returns or strategic spending over the coming months.
Concentrated End MarketsConcentration in obstetrics, gynecology and neonatal niches creates dependence on procedure volumes, hospital budgets and reimbursement trends. Limited product diversification raises exposure to sector-specific headwinds, constraining secular growth potential and amplifying risk from demand shifts.
Utah Medical Products News
UTM FAQ
What was Utah Medical Products’s price range in the past 12 months?
Utah Medical Products lowest stock price was €45.60 and its highest was €60.50 in the past 12 months.
What is Utah Medical Products’s market cap?
Utah Medical Products’s market cap is €186.92M.
When is Utah Medical Products’s upcoming earnings report date?
Utah Medical Products’s upcoming earnings report date is Jul 28, 2026 which is in 51 days.
How were Utah Medical Products’s earnings last quarter?
Utah Medical Products released its earnings results on Apr 23, 2026. The company reported €0.695 earnings per share for the quarter, beating the consensus estimate of N/A by €0.695.
Is Utah Medical Products overvalued?
According to Wall Street analysts Utah Medical Products’s price is currently Overvalued.
Does Utah Medical Products pay dividends?
Utah Medical Products does not currently pay dividends.
What is Utah Medical Products’s EPS estimate?
Utah Medical Products’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Utah Medical Products have?
Utah Medical Products has 3,184,025 shares outstanding.
What happened to Utah Medical Products’s price movement after its last earnings report?
Utah Medical Products reported an EPS of €0.695 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.739%.
Which hedge fund is a major shareholder of Utah Medical Products?
Currently, no hedge funds are holding shares in DE:UTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Utah Medical Products Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.85%
12-Months-Change
Fundamentals
Return on Equity
9.13%
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Company Description
Utah Medical Products
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Technical Analysis
Options Prices
Currently, No data available
---